[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342075-105":59,"doc-detail-342075-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-perioperative-study-of-safusidenib-in-patients-with-idh1-mutated-glioma","A perioperative study of Safusidenib in patients with IDH1-mutated glioma","","Single-arm, open-label perioperative trial evaluates feasibility, pharmacokinetics, and pharmacodynamics of safusidenib given after biopsy and before surgical resection in patients with IDH1-mutated glioma who have not received radiation therapy or chemotherapy. Fifteen participants receive treatment in two parts: Part A biopsy plus one 28-day cycle, followed by maximal safe resection; Part B safusidenib after recovery until disease progression or unacceptable toxicity. Biological activity is measured objectively using progression-free survival and time to next intervention.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-perioperative-study-of-safusidenib-in-patients-with-idh1-mutated-glioma/342075/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-perioperative-study-of-safusidenib-in-patients-with-idh1-mutated-glioma/342075.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the primary purpose of this safusidenib perioperative trial?","Question",{"text":112,"@type":113},"To assess the feasibility and the pharmacokinetics and pharmacodynamics of safusidenib when given after biopsy and before surgical resection in IDH1-mutated glioma.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are participants treated in this study (Part A and Part B)?",{"text":117,"@type":113},"Part A includes biopsy followed by one 28-day cycle of safusidenib, then maximal safe tumor resection. Part B continues safusidenib after recovery until disease progression or unacceptable toxicity.",{"name":119,"@type":110,"acceptedAnswer":120},"How will anti-tumor activity be evaluated?",{"text":121,"@type":113},"Anti-tumor activity will be assessed using progression-free survival and time to next intervention.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342075,1790194478,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","FUTURE ONCOLOGY  \n2024, VOL. 20, NO. 33, 2533–2545  \n[https://doi.org/10.1080/14796694.2024.2383064](https://doi.org/10.1080/14796694.2024.2383064)  \nCLINICAL TRIAL PROTOCOL     \nA perioperative study of Safusidenib in patients with IDH1-mutated glioma  \nSarah A Caina, Monique Toppb, Mark Rosenthalb, Robert Toblerc, Saskia Freytagc, d, Sarah A Bestc, d,  \nJames R Whittle* ,‡,b, c, d and Katharine J Drummond** ,‡, a, e  \na Department of Neurosurgery, Royal Melbourne Hospital, Parkville, 3052, Australia; b Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, 3000, Australia; c Personalised Oncology Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, 3052, Australia; d Department of Medical Biology, University of Melbourne, Parkville, 3052, Australia; e Department of Surgery (Royal Melbourne Hospital), Melbourne Medical School, Faculty of Medicine, Dentistry & Health Sciences, The University of Melbourne, Parkville, 3052, Australia  \nABSTRACT  \nThis is a single arm, open label perioperative trial to assess the feasibility, pharmacokinetics and pharmacodynamics of treatment with safusidenib following biopsy, and prior to surgical resection in patients with IDH1 mutated glioma who have not received radiation therapy or chemotherapy. Fifteen participants will receive treatment in two parts. First, biopsy followed by one cycle (28 days) of safusidenib, an orally available, small molecular inhibitor of mutated IDH1, then maximal safe resection of the tumor (Part A) . Second, after recovery from surgery, safusidenib until disease progression or unacceptable toxicity (Part B) . This research will enable objective measurement of biological activity of safusidenib in patients with IDH1 mutated glioma. Anti-tumor activity will be assessed by progression free survival and time to next intervention.  \nClinical Trial Registration: NCT05577416 ([ClinicalTrials.gov](ClinicalTrials.gov))  \nPLAIN LANGUAGE SUMMARY  \nAdult low-grade gliomas (aLGG) are primary brain cancers, defined by mutations in IDH1 or IDH2 . When the IDH gene becomes abnormal (mutated), production of a metabolite that causes cancer cells to grow is increased. These tumors grow slowly but invade the normal functioning brain, making them nearly impossible to cure. The current standard of care treatment includes surgery, followed by radiation therapy and chemotherapy, the timing of which depends on the risk of cancer regrowth. Some patients may be suitable for monitoring with MRI scans alone, however recurrences will inevitably occur. Recently developed targeted mutant IDH inhibitors for aLGG patients maybe beneficial both at diagnosis and recurrence. Notably, early treatment prior to radiation therapy and chemotherapy delays growth of aLGG and the need for subsequent radiation therapy and chemotherapy. Nevertheless, most patients will eventually suffer further tumor growth and the optimal timing and sequencing of these therapies remains an area of active research. This research investigates the mutant IDH1 inhibitor safusidenib. The researchers are conducting an innovative clinical trial where patients with aLGG, who have not received radiation therapy or chemotherapy, are treated with safusidenib following a biopsy and prior to surgical removal of their tumor. In this study they investigate whether this trial design is safe and feasible, and how safusidenib works; with the goal to better understand the optimal use of IDH inhibitors for patients with aLGG.  \nARTICLE HISTORY  \nReceived 21 May 2024 Accepted 18 July 2024  \nKEYWORDS  \nAB-218; isocitrate dehydrogenase 1; IDH1; low grade glioma; Phase 0; safusidenib; window of opportunity  \n1. Introduction  \n1.1. Background & rationale  \nThe incidence of primary malignant brain tumors is approximately 7 per 100,000 individuals, of which 30% are diffusely infiltrating lower-grade (WHO grade 2) gliomas [1] . Adult low-grade gliomas (aLGG) are defined by mutations in IDH1 or IDH2 and grow slowl","cbCaich5IH6Qdzul","https://ap.wps.com/l/cbCaich5IH6Qdzul","pdf",1492659,13,"English","# Abstract\n# Plain language summary\n# Article history\n# Keywords\n# 1. Introduction\n## 1.1 Background & rationale","[{\"question\":\"What is the primary purpose of this safusidenib perioperative trial?\",\"answer\":\"To assess the feasibility and the pharmacokinetics and pharmacodynamics of safusidenib when given after biopsy and before surgical resection in IDH1-mutated glioma.\"},{\"question\":\"How are participants treated in this study (Part A and Part B)?\",\"answer\":\"Part A includes biopsy followed by one 28-day cycle of safusidenib, then maximal safe tumor resection. Part B continues safusidenib after recovery until disease progression or unacceptable toxicity.\"},{\"question\":\"How will anti-tumor activity be evaluated?\",\"answer\":\"Anti-tumor activity will be assessed using progression-free survival and time to next intervention.\"}]","A perioperative study of Safusidenib in patients with IDH1-mutated glioma | PDF",1790045071,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a071bdbb99a6f18330836f3db372d75b.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87ff6614994f4862fbc7a83d27a0a64d.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/968830fce549d1f015823bbb69b8185c.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47fa6d204855fce47d54f102e2cfea63.webp",980,1268]